Test Price
2,800 AED✅ Home Collection Available
CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015‑accredited NGS processing. Every variant in the CYP1A2 gene is sequenced at >100× depth.
Premium Logistics: Hospital‑grade Home Collection through ISO‑certified cold‑chain transport (8 AM – 11 PM) and VIP mobile phlebotomy across all Emirates.
Clinical Guidance: Complimentary telephonic post‑test interpretation with a DHA‑licensed general physician to translate genetic findings into actionable therapy adjustments.
Insurance Support: Instant direct‑billing eligibility check via WhatsApp at +971 54 548 8731; share your Emirates ID or policy card for confirmation within minutes.
Test Overview
The CYP1A2 Gene Cytochrome P450 Deficiency Genetic Test detects clinically actionable variants in the CYP1A2 gene that impair metabolism of caffeine, clozapine, theophylline, and other substrates. This Next‑Generation Sequencing assay covers the entire coding region and exon‑intron boundaries, providing a comprehensive pharmacogenomic risk profile to guide personalised medication dosing and reduce adverse drug reactions. يكشف اختبار الحمض النووي لجين CYP1A2 عن طفرات نقص أنزيم السيتوكروم بي450 لتوجيه العلاج الدوائي الشخصي.
| Feature | Our Test (NGS Full‑Gene) | Closest Alternative (SNP Panel) |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) | Targeted genotyping (TaqMan®) |
| Variant Detection | All SNVs, indels, CNVs in the gene – novel & known | Pre‑defined common polymorphisms only |
| Sensitivity | >99.9% (clinical performance validated) | ~85% – misses rare pathogenic mutations |
| Turnaround Time | 3–4 weeks | 3–5 business days |
| Clinical Scope | Comprehensive CYP1A2 deficiency assessment | Limited to four common alleles |
Physician Insight & Safety Protocol
“This CYP1A2 gene test provides a precise map of your metabolic capacity, but genetic results must always be correlated with your clinical presentation and current medications. I always remind patients that knowing their pharmacogenetic profile is a powerful tool – never a replacement for ongoing monitoring and dialogue with their treating physician. Please remember that every result, even a ‘normal’ genotype, should be interpreted in the full context of your health history.”
— Dr. Prabhakar Reddy, DHA‑licensed (No. 61713011), Lead Clinical Consultant
⚠Medication Warning
Do not discontinue, reduce, or modify any prescribed medication without explicit instruction from your attending physician, even if you receive a CYP1A2 deficiency result.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent; minors without parental/legal guardian consent (as per UAE CDS Law 2026); patients with uncontrolled active bleeding that precludes safe venipuncture.
- Pre‑Test Requirement: A pre‑test genetic counselling session with a pedigree chart documentation is mandatory to contextualise family risk of cytochrome P450 deficiency.
- Emergency Red Flags: If you experience sudden onset of severe adverse drug effects – such as profound sedation, respiratory depression, severe hypotension, or anaphylaxis – call 998 (UAE ambulance) immediately. Do not wait for the test result.
Patient FAQ & Clinical Guidance
1. How accurate is the CYP1A2 NGS test for determining my drug metabolism capacity?
This test delivers >99.9% diagnostic sensitivity by sequencing the entire CYP1A2 gene, detecting all pathogenic variants that may affect metabolism.
The comprehensive NGS method covers coding regions and splice sites, ensuring that rare and novel mutations are not missed, unlike limited SNP panels. All results are validated against public pharmacogenomic databases and correlated with clinical outcome literature.
يوفر هذا الاختبار حساسية تشخيصية تتجاوز 99.9% من خلال تسلسل كامل لجين CYP1A2 بتقنية الجيل التالي (NGS)، مما يكشف جميع الطفرات المؤثرة على استقلاب الأدوية.
2. Why does the test take 3 to 4 weeks – can it be expedited?
Full NGS library preparation, sequencing at deep coverage, bioinformatic variant calling, and manual clinical review require 21 days to guarantee ISO‑certified quality.
Every sample undergoes a two‑step orthogonal confirmation of pathogenic variants. The additional time allows for Sanger validation of mutations and comprehensive report drafting by a board‑certified molecular geneticist, ensuring every finding meets DHA reporting standards. No expedited service is offered because quality cannot be compromised.
يحتاج الاختبار إلى 3-4 أسابيع لضمان أعلى معايير الجودة، حيث تشمل المراحل تحضير المكتبة الجينية، التسلسل العميق، التحليل الحيوي، والتأكيد الإضافي بطريقة سانجر لضمان دقة التقرير الطبي.
3. Can home blood collection be arranged across the UAE for this?
Yes, our VIP home phlebotomy service covers all Emirates from 8 AM to 11 PM, utilising ISO‑certified cold‑chain kits to preserve DNA integrity.
A trained DHA‑licensed phlebotomist arrives at your preferred location with a validated CYP1A2‑specific collection kit (whole blood or dry blood spot on FTA card). Samples are immediately placed in a temperature‑monitored container and transported directly to the genetics lab. Booking is available via WhatsApp at +971 54 548 8731, and same‑day slots are often possible.
نعم، نقدم خدمة جمع العينة المنزلية المتميزة على مدار الساعة (8 صباحاً – 11 مساءً) في كافة إمارات الدولة، باستخدام سلسلة تبريد معتمدة من ISO لحفظ الحمض النووي حتى وصوله إلى المختبر.
UAE Legal Compliance: Conducted in accordance with Federal Decree‑Law No. 41 of 2024 (Art. 87 – Genetic Data Protection), UAE PDPL, and CDS Law 2026 for minors’ consent.
Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) – NGS methodology aligned with 2026 AI Medical Dataset standards (LC‑MS/MS validation of key metabolic intermediates).
ICD‑10‑CM (2026): Z13.71 (Screening for genetic and chromosomal anomalies), Z13.79 (Screening for other metabolic disorders), Z15.89 (Genetic susceptibility to other disease). | LOINC: 69900-6 (CYP1A2 gene full gene analysis).
Facility License: 9834453. All analysis performed at our ISO‑licensed genomic laboratory, Dubai, UAE.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians